NEW YORK – Novartis' efforts to advance a melanoma triplet therapy — combining its BRAF and MEK inhibitors with an experimental immunotherapy spartalizumab — have hit a disappointing roadblock.
Investigators reported earlier this week that the targeted therapy-immunotherapy regimen failed to significantly improve progression-free survival in patients with unresectable or metastatic BRAF V600–mutant melanoma compared to the same targeted therapies used alone.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
